Viruses, e.g. bacteriophages and compositions thereof and preparation or purification thereof (C12N7)
C12N icro-organisms or enzymes; compositions thereof (biocides, pest repellants or attractants, or plant growth regulators containing micro-organisms, viruses, microbial fungi, enzymes, fermentates, or substances produced by, or extracted from, micro-organisms or animal material a01n0063000000; medicinal preparations a61k; fertilisers c05f); propagating, preserving, or maintaining micro-organisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000)(11911)
C12N7 Viruses, e.g. bacteriophages; compositions thereof; preparation or purification thereof (medicinal preparations containing viruses a61k0035760000; preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, a61k0039000000)(1017)
FIELD: biotechnology.SUBSTANCE: attenuated influenza A viruses and, vectors on their basis and pharmaceutical compositions containing them are presented. The characterized attenuated influenza A virus, inducing a cross-protective response against influenza A and B virus, contains a chimeric NS fragment comprising a truncated reading frame of NS1 protein and a heterologous sequence of Nep protein gene, derived from a subtype of influenza A virus different from the subtype of said attenuated influenza A virus.EFFECT: invention can be used to prevent or treat infectious diseases, in particular influenza, as well as for the treatment of cancer.48 cl, 6 dwg, 3 tbl, 7 ex
FIELD: biotechnology.SUBSTANCE: ashley strain off cats calicivirus, deposited in FBIS SSC VB Vector under the number V-697 is obtain, having stable infectious activity, adapted to the transplanted cell cultures.EFFECT: strain can be used to study the antiviral activity of drugs against cats calicivirus.6 dwg, 4 ex
FIELD: biotechnology.SUBSTANCE: invention relates to the clinical laboratory diagnosis of virus infections, and may be used for genotyping herpes virus 6 (HHV-6). The method enables to determine one-nucleotide polymorphisms specific for HHV-6A and HHV-6B in the U67 HHV-6 gene via real-time PCR using primers HHV6F 5'-CGGATACAGTAAGACGGGATAT-3' and HHV6R 5'-ACGTAAGCTTGCACAATGC-3' and two fluorescently labeled probes HHV6AZ F1-GCAATAGATTTGAGAACGCGCGGCAT-Q1 and HHV6BZ F2-GCAATAGATTCGGAAATGCGGCAT-Q2, where the presence of HHV-6A or HHV-6B is indicated when the exponential accumulation of the fluorescence signal is registered in the respective probes channels. The invention may be used for genotyping herpes virus 6 (HHV-6).EFFECT: rapid and reliable identification of viruses HHV-6A and HHV-6B.2 dwg, 1 ex
FIELD: biotechnology.SUBSTANCE: submitted strain A/17/South Africa/2013/01 (H1N1)pdm09 is a reassortant obtained by crossing of wild virus A/South Africa/3626/2013 (H1N1)pdm09 with virus A/Leningrad/134/17/57 (H2N2) - donor of attenuation, harmless to humans. The strain of live influenza A/17/South Africa/2013/01 (H1N1)pdm09 is characterised by a set of symptoms: antigenic specificity of the epidemic virus A/17/South Africa/3626/2013 (H1N1)pdm09, temperature sensitivity and cold adaptation, harmless to laboratory animals, which correlates with human attenuation. The reassortant has inherited the genes coding surface virus antigens - hemagglutinin (HA) and neuraminidase (NA) from the epidemic parent virus, and six genes coding internal non-glycosylated proteins from the attenuation donor.EFFECT: strain can be used in practical health care to prevent the incidence of influenza in adults and children.5 tbl
FIELD: biotechnology.SUBSTANCE: diagnostic strain of RN2/66-human A (H7N2) influenza virus was obtained by crossing the equine influenza A/horse/Prague/1/1956(H7N7) virus with the cold-adapted vaccine strain A/17/California/66/395(H2N2) based on the attenuation donor A/Leningrad/134/17/57(H2N2). The strain contains the neuraminidase of the influenza virus subtype N2 A/California/1/1966 (H2N2) and influenza A/horse/Prague/1/1956 (H7N7) hemagglutinin. The RN2/66-human A(H7N2) strain actively multiplies in developing chick embryos at the optimum temperature of 33°C, which allows to accumulate viral material for subsequent purification and concentration. The RN2/66-human A (H7N2) strain can be used for solid-phase inhibition of neuraminidase activity to analyse background values of serum antibodies to influenza neuraminidase N2 in the human population and their changes as a result of infection/vaccination.EFFECT: improved strain properties.2 dwg, 1 tbl, 2 ex
FIELD: biotechnology.SUBSTANCE: inventions relate to recombinant nonpathogenic Marek's disease virus (rMDVnp) representing a recombinant herpesvirus of turkeys (rHVT) and to the vaccine containing such virus and to the way of protecting hens from infectious laryngotracheitis virus (ILTV) and Newcastle disease virus (NDV). The presented virus contains the first nucleic acid inserted in the first unnecessary region of rMDVnp genome and the second nucleic acid inserted in the second unnecessary region of rMDVnp genome. The first nucleic acid comprises of a nucleotide sequence coding gD and gI ILTV proteins. The second nucleic acid contains a nucleotide sequence coding a Newcastle disease virus fusion protein (NDV F). The first unnecessary region and the second unnecessary region either are one and the same unnecessary region, or the first unnecessary region is a US2 region and the second unnecessary region is a UL7/8 region.EFFECT: inventions allow for obtaining a stable means of protection from ILTV and NDV.10 cl, 2 dwg, 5 tbl, 6 ex
FIELD: biotechnology.SUBSTANCE: invention relate to the virus particle is released after infection of human cytomegalovirus cells (HCMV), its use in the prevention or treatment of disease by the formation of neutralising antibodies against at least one antigenic heterologous peptide or by induction of CD8+T-lymphocyte response against such heterologous peptide and a vaccine comprising such a viral particle. The characterized viral particle is surrounded by a lipid membrane in which viral glycoproteins are shipped and contains neither viral DNA nor capsids. The particle comprises a fusion protein comprising one or several parts T-cell antigen pp65 and at least one heterologous peptide, and wherein at least one heterologous peptide amino acid incorporated at position W175 ot A534 of the amino acid sequence of T-cell antigen pp65.EFFECT: increased efficiency of application.23 cl, 5 dwg, 5 ex
FIELD: biotechnology.SUBSTANCE: recombinant strain of VACΔ6 vaccinia virus with broken genes C3L, N1L, J2R, A35R, A56R, B8R on the basis of cloned vaccinia virus (L-IVP strain). The proposed strain is deposited in State Collection of causative agents of viral infections, rickettsiosis of the SBSI of the SSC VB Vector with registration No. V-696 and is designed to produce a bladeless, attenuated live culture vaccine against the natural smallpox and other orthopoxviruses with enhanced immunogenic and protective activity.EFFECT: proposed recombinant strain can be used in medicine to produce a vaccine against natural smallpox and other human orthopoxviral infections.7 dwg, 2 tbl, 13 ex
FIELD: biotechnology.SUBSTANCE: characterised recombinant strain VV-GMCSF-S-Lact is constructed on the basis of the vaccinia virus L-IVP strain, containing deletions of fragments of viral thymidine kinase and growth factor genes with integrated granulocyte-macrophagal colony-stimulating factor (GM-CSF) with structure corresponding to human GM-CSF matrix RNA cDNA in the central part of the viral thymidine kinase gene; and the secreted S-Lact lactaptin gene, encoding a human cappase-casein fragment of 23-134 a.o. with "stitching" to its N-terminus of the GM-CSF signal peptide (MWLQSLLLLGTVACSIS), in the left end region of the viral genome. The human GM-CSF gene is expressed under the control of the natural promoter P7.5k of the vaccinia virus and produces the secreted form of a biologically active human GM-CSF in mammalian cells. The S-Lact gene is expressed under the control of the synthetic VACV promoter P7.5synth and produces the secreted oncotoxic protein lactaptin.EFFECT: strain has targeted oncolytic activity against human breast cancer cells in vitro and in vivo and is deposited in SVC of viral infections pathogens and rickettsiosis of FBIS SSC VB Vector under the number V-690.6 dwg, 1 tbl, 5 ex
FIELD: biotechnology.SUBSTANCE: method includes obtaining a substance of influenza virus, a simultaneous introduction of a hardener and charged water-soluble polyeloctrolyte in the virus-containing substance to reach the final concentration of the polyelectrolyte and hardener which does not cause a phase separation in the medication solution. Further, the microcapsules are produced resulting from a composite coacervation of the charged polyelectrolyte and the hardener with a formation of a complex by freezing the solution at a speed of 0.1-3.0°C per minute to the temperature which is lower than the glass transition temperature of amorphous phase remaining after the ice crystallization and freeze-drying of the final microcapsules. The substance of the influenza virus is produced with a specific activity of not less than 7.0 lg EID50/0.5 ml in a serum-free medium containing a proteolytic enzyme in the amount of 0.25-50.0 mcg/ml and soy peptone stabiliser in a concentration of (0.5-4.0) wt %. Stabilizing soy peptone additives and sucrose are added to the purified substance together with the polyelectrolyte and hardener. Carbopol is used as a polyelectrolyte and gelatose is used as a hardener at the following quantitative component content in the resulting liquid substance prior to microencapsulation: soy peptone - (0.007-0.015) g/0.5 ml; sucrose - (0.007-0.015) g/0.5 ml; gelatose - (0.007-0.015) g/0.5 ml; carbopol - (0.00005-0.0001) g/0.5 ml; liquid nutritional medium containing influenza virus with a titre of not less than 107.0 EID50. The rest is up to 0.5 ml.EFFECT: use of this method for producing live-culture influenza vaccine in microcapsules provides for a higher immunogenicity in intranasal application due to increasing the adhesion of microcapsules to nasal mucosa.3 cl, 6 ex, 1 tbl, 1 dwg
FIELD: biotechnology.SUBSTANCE: vaccine includes a viral FMD antigen, aluminium hydroxide, saponin, and chitosan succinate sodium salt additionally used as an adjuvant,at the following component ratio, wt %: 0.25-0.75 of saponin, 0.5-1.5 of chitosan succinate sodium salt, 15.0-25.0 of aluminium hydroxide in glycol buffer with of pH 7-8.6, and FMD viral antigen - the rest. The group of inventions relates to a method for production of a vaccine against foot and mouth disease.EFFECT: application of this group of inventions allows to increase the target product immunogenicity during animal vaccination against the foot and mouth disease.5 cl, 9 ex, 1 tbl
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Method of detecting contamination with viruses of cell culture by immunoperoxidase method is described, involving reaction of antigen with labelled antibodies in clean cell culture and accounting of reaction results by color density of formed complex under microscope. Wherein reaction uses tablets with analyzed cell culture, contaminated with diarrhoea virus, and after adding into tablet wells of 0.10–0.12 ml of specific homologous serum diluted by 1:64 – 1:128 it is incubated, washed, then 0.10–0.12 ml of anti-specific immunoenzymometric conjugate is introduced, consisting of peroxidase marked antibodies against globulins of cattle blood serum, it is incubated, washed, substrate mixture is introduced consisting of 5-aminosalicylic acid and hydrogen peroxide, and 30–40 minutes later results are accounted under light microscope by formation of brown color in virus-containing cells. Invention improves control system of cell lines latent contamination with viruses used in laboratory practice and biological industry.EFFECT: invention allows to prevent biological contamination and is extremely important stage in production of vaccines and diagnostic preparations; this method can be used for certification at absence of viruses in again coming cell cultures; invention is practically feasible, cheap method of monitoring of cell cultures for content of virus and may be recommended for extensive use both in scientific research and practical virological laboratories, and in production in making diagnostic preparations and vaccines.1 cl, 2 ex
FIELD: biotechnology.SUBSTANCE: method for production of recombinant pseudoadenovirus particles (RPAN) concentrate, expressing the hemagglutinin gene of influenza a/california/07/2009(H1N1) is proposed. The method comprises: obtaining of a production cell culture; preparation of disaggregated starting RPAN culture samples; single-round infection of the production suspension cell culture, thereby obtaining a RPAN-containing crude suspension, with subsequent cell mass precipitation by centrifugation and spent culture medium diverting; precipitated cell mass resuspension in lysis buffer, then one-time freezing followed by suspension thawing the slurry and RPAN separation from the disrupted cells successively by centrifugation, ultrafiltration, anion exchange chromatography, size exclusion chromatography, sterile filtration to yield a sterile pharmaceutical grade RPAN concentrate with high level ofchromatographic purity.EFFECT: method allows to obtain an increased yield of RPAN and a possibility to obtain a concentrate with high titers and chromatographic purity, that meets the quality of a pharmaceutical product suitable for industrial production of influenza vaccines.1 dwg, 1 tbl, 5 ex
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and virology. Described is bacteriophage F510/08, comprising genome, which contains nucleic acid sequence SEQ ID NO: 4. Bacteriophage shows activity upon Pseudomonas aeruginosa. Invention also describes versions of pharmaceutical composition containing such bacteriophage, and methods of therapy for treatment and prevention of bacterial infection.EFFECT: presented group of inventions can be applied in medicine.23 cl, 327 dwg, 7 tbl, 7 ex
FIELD: biotechnology.SUBSTANCE: method comprises culturing bacterial cells of host strain in the absence of extraneous microflora, phage lysate preparation and purification by precipitation and/or filtration. After 30-120 minutes after culturing initiation, at the optimum growth temperature for the culture of rapidly growing host strain, every 30-60 minutes, smears are made from the host strain culture from the surface of solid nutrient medium or from a liquid culture medium. The smears are stained with a solution of acridine orange in the final concentration of 0.001% to 0.02% or acridine yellow solution to the final concentration of 0.01% to 0.2%. The stained smear is microscoped in fluorescence microscope. Time is set for inoculating the mother bacteriophage at achievement in the stained smear of not less than 50% in relation to the total host strain cells proportion of orange acridine stained cells, fluorescing with orange or red shades, or the proportion of yellow acridine stained cells fluorescing with yellow or orange shades, at achevement of less than 10% in relation to the total host strain cells proportion of cells with non-uniform fluorescence that is paired pole adjoining cells in the form of rods with irregular or spherical cytoplasm fluorescent and spherical or ellipsoidal cells with slightly fluorescenting central section. Then mother bacteriophage is inoculated.EFFECT: stability of achieving high bacteriophage titer upon phage lysate production in a changing nutritive medium formulations, and increase in the range of variations of the indicator values of the host strain and bacteriophage culturing.11 ex
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and virology. Production of optimized HA polypeptides of influenza virus H1N1 is described, causing immune response with wide spectrum of activity in relation to influenza virus H1N1 isolates. Optimized HA polypeptides were developed by series alignments of HA protein sequences and subsequent formation of consensus sequences based on structure of certain viruses H1N1 recovered from 1918 at 2011. Invention also describes composition, fused proteins and VLP containing HA polypeptides. Invention also describes sequence of nucleic acids, subjected to optimization of codons coding HA polypeptides and methods for inducing immune response against influenza virus in subject.EFFECT: disclosed group of inventions can be used in medicine.23 cl, 7 dwg, 3 ex
FIELD: medicine; biotechnology.SUBSTANCE: invention relates to biotechnology, virology, and medicine. Virions of adeno-associated virus (AAV) with optional capsid protein are presented, where AAV virions show high infection load of retinal cell at intravitreal injection compared with wild type AAV. Methods of delivering gene product in retinal cell of person and methods of treating eye diseases are also described.EFFECT: virions of adeno-associated virus with optional capsid and methods for using them are presented.24 cl, 25 dwg, 2 tbl, 3 ex
FIELD: biotechnology.SUBSTANCE: invention relates to a method of purifying filamentous bacteriophage M13. Method involves removal of bacterial mass after producing bacteriophage by first and second successive centrifugation followed by first purification of supernatant of bacteriophage by isoelectric precipitation with a reagent at pH 4.2, further third centrifuging and re-suspension of precipitate with bacteriophage, as well as repeated purification of suspension of bacteriophage by isoelectric precipitation with a reagent at pH 4.2 and fourth centrifugation of precipitate with bacteriophage to produce end product. For isoelectric precipitation agent used is sodium acetate buffer with pH = 4.2 in ratio to supernatant of bacteriophages of not less than 3:1 at first isoelectric precipitation, precipitate with bacteriophage after third centrifugation is re-suspended in TBS-buffer, and during repeated purification of re-suspended bacteriophage by isoelectric precipitation, sodium acetate buffer with pH = 4.2 is used in ratio to re-suspended bacteriophage of not less than 1:1. First and second centrifugation is carried out at 5,000 rpm and 12,000 rpm for 10 minutes at 20 °C, and third and fourth centrifugation is carried out at 10,000 rpm for 10 minutes at 4 °C.EFFECT: invention provides a higher level of sterility and purity of bacteriophage, especially in small quantities thereof using a simpler technique.1 cl, 7 tbl, 9 ex
FIELD: medicine.SUBSTANCE: invention relates to medicine and concerns a method for prediction of relapse vulvar I and II stage. Proposed method consists in determining in tumour tissue a DNA of human papilloma virus by method of polymerase chain reaction. In the patients with stage I disease in the presence of virus, predict relapse by 57.3±0.3 months, in the absence of virus – through 36±0.12 months, in the patients with II stage of disease in the presence of virus occurrence of relapse is predicted through 48±0.2 months, while the absence of virus – through 27.1±0.08 months.EFFECT: invention can be used in gynecology for prediction of recurrent carcinoma of vulva.1 cl, 1 tbl, 4 ex
FIELD: medicine.SUBSTANCE: invention relates to virology. Attenuated strain “SKA-2015 VNIIVViM” of african swine fever virus serotype VIII is disclosed. Strain is produced by intermittent passages and selection of virulent strain "Stavropol 01/08" in primary cell culture of LS and transplantable hybrid cell line A4C2/9k and it is deposited in State collection of strains of microorganisms GNU Rosselhozakademii VNIIVViM under No. 1847.EFFECT: strain "MSC-2015 VNIIVViM" can be used during virological, molecular-genetic research, studying immunogenesis of disease, development of diagnostic and vaccine preparations.1 cl, 4 tbl, 4 ex
FIELD: biotechnology.SUBSTANCE: present invention relates to biotechnology. Method for production of influenza virus with monoglycosylated hemagglutinin-antigen (HA-antigen) is disclosed. Method involves cultivation of influenza virus, containing hemagglutinin-antigen in specific pathogen free (SPF) chicken egg with embryo with an effective amount of mannosidase inhibitor, concentration of which is sufficient for inhibiting of α-mannosidase I in the path of N-glycosylation followed by extraction of produced influenza virus. Further contact of extracted influenza virus with endoglycosidase (EndoH) leads to production of influenza virus, having monoglycosylated influenza virus HA-antigen.EFFECT: disclosed method enables to obtain influenza virus with monoglycosylated hemagglutinin-antigen (HA-antigen) with high yield using specific pathogen free (SPF) chicken eggs with embryo, and can be used for producing monoglycosylated hemagglutinin-antigen in production of vaccines.19 cl, 4 dwg, 4 ex
FIELD: biotechnology.SUBSTANCE: disclosed is viral vector cleaning method. Method involves introduction of exogenous gene coding receptor and representing gene interest in packing cell line, followed by cells culturing, collection of supernatant containing viral vector particles carrying receptor on its outer shell. Subsequent supernatant incubation with ligand, connected with fragment, which can be extracted from supernatant, leads to ligand binding with receptor, as a result of which obtained ligand-viral vector complex can be extracted from supernatant to produce viral vector purified particles.EFFECT: proposed cleaning method is effective and provides high level of extraction, and can be used in biotechnology for viral vectors cleaning.15 cl, 3 dwg, 4 tbl, 6 ex
FIELD: biotechnology.SUBSTANCE: invention relates to medical biotechnology. Methods of determining biological activity of monocomponents in associated combined di-and trivaccines are disclosed, which contain vaccine strains of measles virus (l-16), epidemic parotitis (l-3) and/or rubella (Orlov).EFFECT: proposed methods make it possible to simplify technology of control of vaccine preparations and reduce cost of production of vaccines.3 cl, 5 tbl, 3 ex
FIELD: biotechnology.SUBSTANCE: present invention relates to a method for capturing virus-like particles of interest from a mixture containing destroyed plant cells. Method comprises use of an expanded bed of adsorbent containing resin material, balancing resin material at pH 6.0–8.0 and adding mixture to expanded bed of adsorbent for binding of virus-like particles. Degree of expansion of expanded bed is equal to 1–5. Further, adsorbent is washed. Virus-like particles are eluted from adsorbent.EFFECT: high purity of extracted particles, high process efficiency.17 cl, 9 tbl
FIELD: veterinary science.SUBSTANCE: invention relates to veterinary virology and biotechnology and concerns strain of virus nodular dermatitis of cattle (VND CATTLE). Described strain is recovered from cows, patients of nodular dermatitis, and deposited in Collection of strains of FGBU "VNIIZT" under registration number - VND KRC/Dagestan/2015 (diagnostic). Strain is reproduced in cultures of cells YDK-04 and TY during 2÷3 days and accumulated in titre from 4.5 to 5.5 lg TCD50/cm3, preserves initial characteristics when passaging in cultures of cells YDK-04 and TY during 5 passages.EFFECT: obtained on its base antigen material can be used for making diagnostics and specific prevention of nodular dermatitis CATTLE.1 cl, 5 dwg, 6 tbl, 7 ex
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and concerns influenza virus strain. Presented strain of virus of bird flu A/Common Muskrat/Chany Lake/226/05 H2N2-subtype, deposited in collection of microorganisms of Federal budgetary institution of science "State Research Centre for virology and biotechnology "Vector" under registration number V-623.EFFECT: invention can be used to study the efficacy of therapeutic and preventive preparations for influenza, for preparation of antigen-containing substrate and serum for serodiagnosis of influenza H2-subtype in RTGA, for use as a control reference sample when evaluating specificity of test systems based on polymerase chain reaction, as well as for studying efficacy of antiviral preparations in vitro and in vivo.1 cl, 4 tbl, 4 ex
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and concerns influenza virus strain. Proposed a reassortant vaccine strain A/17/silver gull/Sarma/06/887 (H6N1). Strain is produced by crossing virus A/Silver gull/Sarma/51c/2006 (H6N1) with strain A/Leningrad/134/17/57 (H2N2) – donor of attenuation, harmless for adults and children. Strain A/17/silver gull/Sarma/06/887 (H6N1) actively propagates in developing chicken embryos at optimal temperature 33 °C, is characterised by heat sensitivity, cold adaptation and attenuation and immunogenicity for laboratory animals. Strain is deposited in the State collection of viruses FSBU of federal State Research Centre of epidemiology and microbiology of the honorary academician N.F. Gamaley of Ministry of health of the RF at № 2807.EFFECT: invention can be used for producing live influenza vaccine.1 cl, 1 dwg, 2 tbl, 2 ex
FIELD: medicine.SUBSTANCE: invention refers to medical virology and concerns influenza virus strain. Disclosed a vaccine strain A/17/Hongkong/2014/8296 (H3N2)-reassortant, produced by crossing "wild" virus A/Hongkong/4801/2014 (H3N2) with cold-adaptive heat-sensitive virus A/Leningrad/134/17/57 (H2N2) – attenuation donor, safe for humans. Presented strain A/17/Hongkong/2014/8296 (H3N2) actively propagated in chicken embryos at optimal temperature of 32 °C, characterized by temperature sensitivity and cold adaptation and safety for laboratory animals. Strain is deposited in the State collection of viruses FGBU "FNICEM nam. N.F. Gamalei" of the Ministry of Health of Russia, Institute of virology nam. D.I. Ivanovskogo under № 2818.EFFECT: invention can be used in practical health services for preventing influenza incidence in adults and children by a live influenza intranasal vaccine.1 cl, 1 dwg, 5 tbl
FIELD: medicine.SUBSTANCE: invention relates to virology. Disclosed is a vaccine strain V/60/Phuket/2013/26-reassortant, obtained by genetic reassortation of epidemic virus V/Phuket/3073/2013 with cold-adapted temperature-sensitive virus V/USSR/60/69 - attenuation donor, safe for humans. Strain of V/60/Phuket/2013/26 is characterised by temperature sensitivity and cold adaptation and safety for laboratory animals. Strain of V/60/Phuket/2013/26 comprises genes which code surface virus antigens of hemagglutinin (HA) virus and neuraminidase (NA), from an epidemic parent virus V/Phuket/3073/2013 and remaining six genes coding internal non-glycosylated proteins, from attenuation donor V/USSR/60/69.EFFECT: strain of V/60/Phuket/2013/26 can be used in medicine for preventing influenza incidence in adults and children in live influenza intranasal vaccine.1 cl, 4 tbl
FIELD: medicine.SUBSTANCE: invention relates to general and medical virology and concerns influenza A virus. Obtaining new adapted versions of pandemic influenza A(H1N1)pdm09 strain to organisms of different laboratory animals, proposed three adapted versions of the pandemic influenza virus obtained from wild-type strain A/Tomsk/273/2010(H1N1pdm09) by multiple passing through lungs of experimental mice. Strain A/Tomsk/273/2010-MA1(H1N1pdm09) passed 7 passages through lungs of mice of line BALB/c, strain A/Tomsk/273/2010-MA2(H1N1pdm09) - 12 passages through lungs of mice of line C57BL/6z, and strain A/Tomsk/273/2010-MA3(H1N1pdm09) - 10 passages through lungs of mice of line CD1. All the above strains cause 100 % death rate among mice, to organisms of which they are adapted. Strain A/Tomsk/273/2010-MA1(H1N1pdm09) is high-fatal not only for mice, to the body of which it was adapted (mice of line of BALB/c), but for mice of opposite line C57BL/6z causing among the last 100 % lethality.EFFECT: obtained strains can be used for studying of mechanisms of adaptation of viral pathogens to new host with evaluation of action of antiviral drugs in treating of influenza disease caused by pandemic VG A(H1N1)pdm09.3 cl, 2 dwg, 5 tbl, 5 ex
FIELD: medicine.SUBSTANCE: invention refers to medical virology and concerns influenza virus strain. Characterized vaccine strain A/17/Bolivia/2013/6585 (H1N1)pdm09 - reassortant, produced by crossing "wild" virus A/Bolivia/559/2013 (H1N1)pdm09 with cold-adapted heat-sensitive virus A/Leningrad/134/17/57 (H2N2) - donor of attenuation, safe for humans. Strain A/17/Bolivia/2013/6585 (H1N1)pdm09 actively propagated in developing chicken embryos at optimal temperature of 32 °C, characterised by thermal sensitivity and cold adaptation and safety for laboratory animals. Reassortant deposited in State collection of viruses of FGBU "FNICEM nam. N.F. Gamalei" of the Ministry of health of Russia Research Institute of virology. D. I. Ivanovskogo under №2809.EFFECT: invention can be used in practical health services for preventing influenza incidence in adults and children.1 cl, 5 tbl
FIELD: biotechnologies.SUBSTANCE: invention relates to biotechnology, virology and immunology. Novel adenovirus strains with an improved seroprevalence are described. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof, and polynucleotides encoding the polypeptides and fragments thereof. Also provided is a vector comprising the isolated polynucleotide according to the invention; adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention, and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. Invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.EFFECT: disclosed group of inventions can be used in medicine.17 cl, 11 dwg, 4 tbl, 6 ex
FIELD: veterinary science.SUBSTANCE: invention relates to veterinary virology and biotechnology and concerns new murrain virus strain epizooticae type A fam. Picornaviridae, genus Aphtovirus, which is deposited in collection of FGBU “VNIISZH” under registration number murrain strain 2166/Krasnodarskiy/2013 (production, control of cattle). Presented strain is reproduced in primary trypsinated monolayer swine kidney cell culture (KC), passaged siberian mountain goat kidney cell cultures (PSGK-30), VHK-21 and IB-RS-2. During 18÷24 h of incubation virus yield in said cell cultures reaches 6.0÷7.33 lg TCD50/cm3. Multiplicity of infection (1÷10 TCD/cell) causes CPP after 5 hours, maintaining initial characteristics, when passaging in cell cultures throughout 5 passages.EFFECT: presented strain may be used for antigenic and immunogenic activity and to produce biopreparations for diagnostics and specific prevention of murrain type A.1 cl, 6 tbl, 6 ex
FIELD: biotechnology.SUBSTANCE: invention relates to a recombinant strain of vaccinia virus (VV). Disclosed recombinant strain VV-GMCSF-Lact is constructed based on strain L-IVP vaccinia virus, containing a deletion of virus thymidine kinase gene fragments and growth factor, in areas which are built: gene of human granulocyte-macrophage colony-stimulating factor (GM-CSF), structure of which corresponds to DNA matrix RNA of human GM-CSF, in central part of virus thymidine kinase gene; and lactaptin gene coding fragment of human kappa casein 23-134 a.o., in left terminal area of viral genome. Human GM-CSF gene is expressed under control of natural promoter P7.5 k vaccinia virus and produces secreted form of biologically active human GM-CSF in cells of mammals. Lactaptin gene is expressed under control of synthetic promoter of vaccinia virus P7.5synth and produces oncotoxic recombinant lactaptin protein. Disclosed strain is deposited in State collection of agents of viral infections and rickettsial diseases of FBIS SSC VB “Vector” under number V-688.EFFECT: described strain has high oncolytic activity on human breast cancer cell and can be used in biotechnology.1 cl, 5 dwg, 4 ex
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology. Disclosed is a self-complementary adeno-associated virus vector for treating motor neuron disorders such as spinal muscular atrophy, amytrophic lateral sclerosis, spinal bulbar muscular atrophy, spinal cerebellar ataxia, primary lateral sclerosis, and traumatic spinal cord injury. Also described are compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to brain and/or spinal cord.EFFECT: disclosed group of inventions can be used in medicine.16 cl, 17 dwg, 4 ex
FIELD: biotechnology.SUBSTANCE: invention relates to production of a bacteriophage. Disclosed method involves inoculation of bacterial cell suspension in the titre of 108-1012 CFU/ml on a dense nutrient medium with the layer thickness from 3 to 25 mm and cultivation with no foreign microflora, when the air layer thickness over the surface of the dense nutrient medium is from 5 to 50 mm and at optimum temperature for a host strain culture growth. In 30-120 minutes after the beginning of culturing every 30-60 minutes smears are taken from the surface of the dense nutrient medium, coloured with an intercalating dye and microscoped. Cultivation is stopped when reaching at least 10 % in relation to the total amount of cells of the host cell fraction strain with heterogeneous fluorescent cytoplasm staining. Then the obtained lawn of the host strain culture is inoculated with a mother bacteriophage in the titre of 107-1010 BFU/ml. Cultivated for 13-15 hours with no foreign microflora, at the air layer thickness over the surface of the dense nutrient medium from 5 to 50 mm and at optimum temperature for the bacteriophage strain culture growth. Obtained a phage lysate when suspending, sucked off the phage lysate into a sterile container and cleaned. Invention provides reaching a stable high titre of bacteriophage (1012-1014 BFU/ml) when producing phage lysates both at varying formulations of nutrient media and increasing the span variation of values of culturing the host strain and the bacteriophage.EFFECT: invention can be used in biotechnology for obtaining products containing bacteriophages.9 cl
FIELD: veterinary science.SUBSTANCE: invention relates to veterinary virology and biotechnology and concerns new murrain virus strain Aphtae epizooticae type A family of Picornaviridae, genus Aphtovirus, deposited in collection of FGBU “VNIIZZH” under registration number murrain strain A No. 2155/Baikal/2013 (industrial). Presented strain is reproduced in monolayer swine kidney cell culture (SC), continuous kidney cell cultures of siberian mountain goat (PSGK-30), VNK-21 and IB-RS-2 during 18÷24 hours of incubation of virus yield in said cell cultures reaches levels of 6.33÷7.5 lg TCD50/cm3. Multiplicity of infection (1÷10 TCD/cell) causes CPP after 5 hours, maintaining initial characteristics, when passaging in cell cultures throughout 5 passages.EFFECT: presented strain may be used for control of antigenic and immunogenic activity and to produce biopreparations for diagnosis and specific prevention of murrain type A.1 cl, 6 tbl, 7 ex
FIELD: veterinary science; biotechnology.SUBSTANCE: invention relates to veterinary virology and biotechnology. Vaccine contains active substance and target additives. As active substance, vaccine contains mixture of avirulent purified antigen material of foot FMD A strains No. 2171/Kabardino-Balkar/2013, A No. 2187/Kuti/2013, Asia-1 No. 1946/Shamir 3/89 and O No. 2123/South Ossetia/2011, obtained from transplantable cell culture VNK-21, representing suspension, containing mainly 146S and 75S immunogenic components of FMD, adjuvants: aluminium hydroxide with saponin and preserving medium in effective ratios.EFFECT: vaccine exhibits high immunogenicity and is capable of providing effective protection against homologous infectious agents, circulating in Transcaucasus, Central Asia, middle and Near East.16 cl, 4 dwg, 7 tbl, 5 ex
FIELD: biotechnology.SUBSTANCE: invention relates to a live attenuated recombinant poliovirus, use thereof to produce vaccines, as an inoculum or for preparing a drug, a method of producing such a vaccine and a method of vaccinating a patient. Described poliovirus has a 5' non-coding region consisting of the 5' non-coding region of Sabin 3, modified so that it does not have a base pair mismatch in stem (a) or (b) of domain V, wherein seven or eight of base pairs in stems (a) and (b) are U-A or A-U base pairs; and a capsid protein from Sabin 1, Mahoney, MEF or Saukett strain.EFFECT: presented inventions can be used to produce safe vaccines with improved immunogenic properties against poliovirus.14 cl, 4 dwg, 7 tbl, 6 ex
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and virology. Described is a self-replicating RNA molecule. Molecule contains first nucleotide sequence coding first protein of herpes virus, and second nucleotide sequence coding second protein of herpes virus. Molecule is intended for producing protein complexes in cell. Invention also discloses alpha-virus replicon particle, containing such RNA molecule, composition containing such alpha-virus, and methods for inducing immune response in subject, using such RNA molecules, alpha-virus, and composition.EFFECT: invention can be applied in medicine.31 cl, 57 dwg, 11 tbl, 7 ex
FIELD: veterinary science.
SUBSTANCE: present invention relates to field of veterinary vaccines, in particular to vector vaccines for poultry based on recombinant nonpathogenic Marek's disease virus (npMDV). Invention also relates to methods and applications, including recombinant npMDV, expression cassette, infected host cell and a vaccine. Recombinant npMDV contains heterologous nucleic acid molecule, wherein said nucleic acid molecule contains from 5′-end to 3′-end in following order: a. core early 1 gene promoter of human cytomegalovirus (hCMV-IE1), where said promoter is presented in SEQ ID NO: 1, (b). protein gene fusion (F) Newcastle disease virus (NDV), c. terminator transcription, d. core chicken beta-actin gene promoter, where said promoter is presented in SEQ ID NO: 4, ie. viral protein gene 2 (VP2) virus infectious bursitis (IBDV) classic type.
EFFECT: vaccine based on recombinant npMDV, can be used for induction of protective immune response in poultry not only against Marek's disease, but also against Newcastle disease and infectious bursitis treatment.
11 cl, 5 dwg, 3 tbl, 8 ex
FIELD: veterinary science.
SUBSTANCE: invention relates to veterinary virology and biotechnology and concerns a vaccine containing an active substance and target additives. As the active substance the vaccine contains a mixture of avirulent purified antigen materials of the foot-and-mouth disease (FMD) virus strains A No. 2171/Kabardino-Balkar/2013, A No. 2187/Kuti/2013, Asia-1 No. 1946/Shamir 3/89 and O No. 2123/South Ossetian/2011, obtained in the VNK-21 passaged cell culture representing a suspension primarily containing 146S and 75S immunogenic components of the FMD virus. Besides, the vaccine contains a maintenance medium and an oil adjuvant in effective ratios. As the maintenance medium Earle's solution is used without serum with addition of enzymatic muscular tissue hydrolysate, casein medium albumen hydrolysate and antibiotics at the pH of 7.4-7.6. Of oil adjuvants the vaccine contains the Montanide ISA-70 or Montanide ISA-206 oil adjuvant produced by “Seppic” (France).
EFFECT: vaccine provides protection against the infection agent circulating in Transcaucasus, Central Asia, Middle and Far East regions.
15 cl, 4 dwg, 8 tbl, 9 ex
SUBSTANCE: group of inventions concerns an isolated polynucleotide molecule of nucleic acid which codes North American porcine reproductive and respiratory syndrome (PRRS) virus, a host cell for generation of PRRS virus, transfected by said polynucleotide molecule, vaccine for protection of pigs against infection with PRRS virus, RNA molecule coding PRRS virus, method of generating a PRRS virus in vitro and plasmid for expression of PRRS virus. Described isolated nucleic acid molecule has a sequence presented in SEQ ID NO: 1, 2, 3, 4 or 6.
EFFECT: disclosed group of inventions enables to obtain an effective immune response in pigs to North American porcine reproductive and respiratory syndrome virus and can be used in veterinary science.
10 cl, 8 dwg, 10 tbl, 8 ex
FIELD: biotechnology.SUBSTANCE: invention relates to a set of oligonucleotide primers for obtaining a primary structure F of Newcastle disease virus gene class I. Presented set consists of three pairs of oligonucleotides having following structure (5′→3′):Fgene 1F - ATGGGCTCCAGATCTTCTACC, Fgene 560RTTAACAAATTGYTGCATCTTCCCG;Fgene 471F - GCATTGCTGCAACCAATGAGG, Fgene 1008RTGAGGTGTCAAGYTCTTCTATCAC;Fgene 898F - CGTGCCACCTACYTGGAAAC, Fgene 1663RTCACATTTTYGTAGTGGCYCTC. Presented oligonucleotides avoid cross-reactions with related species, make it possible to limit manipulation of single-stage procedure of polymerase chain reaction (PCR). Developed primers enable to obtain full information on F genes of Newcastle disease virus, their belonging to any genetic line virus, presence of nucleotide/amino acid substitutes in genome of pathogen.EFFECT: invention can be used for diagnostic purposes for identification of Newcastle disease virus in virology and veterinary science, as well as to solve scientific and research tasks on study of said virus.1 cl, 1 dwg, 2 tbl, 3 ex
FIELD: biotechnology.SUBSTANCE: present invention relates to a method of purifying bacteriophages. Described method includes: a) culturing a bacterial host strain on an appropriate medium, inoculating said culture with a bacteriophage and obtaining a bacteriophage lysate; b) purifying lysate using affinity chromatography; c) using resulting filtrate to prepare a purified bacteriophage, wherein in stage a) bacterial host strain used consists of bacterial cells containing a sequence encoding a fusion protein containing a foreign polypeptide exhibiting an affinity for a chromatography resin used in stage b) and a polypeptide from among structural phage proteins of bacteriophage present in resulting lysate, and said polypeptide having affinity for chromatographic resin, selected from a group comprising His-tag and GST.EFFECT: disclosed invention enables single-stage and simultaneously time-efficient purification of phage preparations for therapeutic purposes and ensures preservation of antibacterial activity of bacteriophage in case of displacement of bacteriophage from resin, and in case of proteolytic release.5 cl, 10 dwg, 1 tbl, 1 ex
FIELD: biotechnology.SUBSTANCE: described is a recombinant attenuated strain of vaccinia virus with broken virulence genes ΔA56RΔB8RΔJ2RΔC3LΔN1L (1421ABJCN) based on cloned LIVP strain of vaccinia virus. Technical result of proposed invention consists in creation using five plasmids integration of highly attenuated recombinant vaccinia virus strain for producing safer live culture of attenuated smallpox vaccine and other orthopoxviruses, pathogenic for humans. Said technical result is achieved by obtaining recombinant strain L-IVP 1421ABJCN vaccinia virus with broken virulence genes A56R, B8R, J2R, C3L, NIL, intended for producing live culture of attenuated smallpox virus vaccine and other orthopoxviruses.EFFECT: invention can be used in medicine, biotechnology, particularly genetic engineering for producing live culture of attenuated smallpox vaccine and other orthopoxviruses, pathogenic for humans.1 cl, 9 dwg, 5 tbl, 12 ex
FIELD: biotechnologies.SUBSTANCE: invention relates to biotechnology and virology. Described is method of purifying vectors based on recombinant adenoassociated virus (rAAV). Vectors based on recombinant AVV according to invention deprived of technological impurities, including components of product, such as cell nucleic acids, cell proteins, helper virus and components.EFFECT: method involves bringing stream of initial materials in contact with medium for chromatography on apatite in presence of polyethylene glycol (PEG) and elution of rAAV particles using elution buffer containing less than 3 % (wt/Vol) PEG.34 cl, 7 dwg, 6 tbl, 13 ex
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology, virology and medicine. Diagnostic influenza virus strain RN9/13-human A (H6N9) is obtained by crossing apatogenic bird flu virus a/silver gull/Sarma/51 c/06 (H6N1) with cold-adapted vaccine strain a/17/Anui/2013/61(H7N9) based on attenuation donor A/Leningrad/134/17/57 (H2N2). Strain has neuraminidase influenza virus subtype N9 A/Anui/1/2013(H7N9) and avian influenza virus hemagglutinin and/silver gull/Sarma/51c/06(H6N1). Strain RN9/13-human A(H6N9) actively propagates in developing chicken embryos at optimum temperature of 33 °C, which enables to accumulate viral material for further purification and concentration.EFFECT: strain RN9/13-human A(H6N9) can be used for detection of antibodies to influenza virus neuraminidase N9 in blood serum using solid-phase reaction of inhibiting neuraminidase activity and post-adsorption micro-neutralisation reaction in MDCK cell culture.1 cl, 2 dwg, 1 tbl, 1 ex
FIELD: pharmaceutics.SUBSTANCE: set of inventions concerning epitope specific for hepatitis B virus (HBV), polynucleotide coding epitope, expression of recombinant vector, recombinant microorganism, virus or cells of mammals, method of producing epitope and method for producing antibody specifically bound to epitope. Described epitope is conservative position HBV, which is not subjected to mutagenesis.EFFECT: presented group of inventions can be used to obtain compositions with high therapeutic efficiency due to absence of possibility of mutations in used epitope.22 cl, 8 dwg, 5 tbl, 3 ex
FIELD: bioengineering.SUBSTANCE: claimed invention discloses the composition including the recombinant modified virus of the Ankara variolovaccine. Note here that the said recombinant modified virus of the Ankara variolovaccine is the EEV-type without directed infective specificity.EFFECT: invention can be used in cancer or infectious disease treatment.11 cl, 3 dwg, 3 tbl, 2 ex